BDMD

Enhanced U.S. Presence Centralizes Operations as Company Executes Global Growth Strategy NEW YORK, June 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the relocation of its global headquarters to the U.S., with the establishment of a new corporate office in New York, NY. The relocation follows the December 2025 appointment of Mark Saxton as CEO of Baird Medical's U.S. subsidiary to lead domestic operations, commercial expansion, and market development, establishing a Company beachhead in a premier global healthcare and financial hub. "Relocating our global headquarters to New York marks the next step in Baird Medical's evolution as we continue to expand our commercial footprint and execute on our growth strategy as a leading global medtech company for innovative, minimally invasive ablation technologies and beyond," said Mark Saxton, Chief Executive Officer of Baird Medical U.S. "This move provides more efficient access to the world's most sophisticated healthcare investors and better positions us to support our growing sales force and physician and KOL network across the country." While Baird Medical's physical presence will continue to span key healthcare markets globally, the new global headquarters will serve as a central hub for corporate leadership and strategic initiatives. "Our U.S. operational buildout is progressing on schedule," added Haimei Wu, Chairwoman & CEO of Baird Medical. "We are building the infrastructure necessary to scale the business, making strategic investments in commercial and clinical initiatives to deliver safe, effective, and minimally invasive treatment solutions to patients worldwide." About Baird Medical Baird Medical is a pioneering medical device company specializing in minimally invasive diagnostics, treatment, and surgical robotic systems. Driven by a mission to enhance patient outcomes through precision technology, the Company extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions are utilized by over 30 prestigious U.S. institutions, including the Mayo Clinic, Columbia University Medical C...

Full year 2025 revenue of $22.5 million, impacted by policy-driven slowdown in Mainland China Advancing global expansion with appointment of seasoned commercial leader, Mark Saxton, as CEO of Baird Medical U.S. to lead commercial ramp in the United States NEW YORK, April 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its financial results for the full year ended December 31, 2025 and provided an update on key strategic and operational initiatives. "2025 was an important period in Baird's evolution as we began executing on our strategy to become a global, innovation-driven med tech organization," said Mrs. Haimei Wu, Chairman and Chief Executive Officer of Baird Medical. "The commercial environment in Mainland China was particularly challenging in light of recent policy changes, which has made our efforts to broaden the Company's geographic footprint of great importance. To that end, we reached an important milestone in the fourth quarter with the appointment of Mark Saxton as the CEO of Baird U.S. to lead our commercial ramp in this key market. Mark has built a sterling reputation over the last 25 years at companies including NeuroPace, Covidien and Smith + Nephew, launching a broad range of innovative technology solutions and growing them into market leaders. We have great confidence in the potential of our technology to thrive in the U.S. under Mark's leadership." "Our Microwave Ablation (MWA) technology offers patients a truly minimally invasive alternative that delivers excellent patient outcomes and reduces the uncertainty associated with watchful waiting. My early conversations with U.S. surgeons have been deeply encouraging and have only strengthened my conviction that there is a real, unmet need for novel solutions like MWA to address the needs of these patients," said Mark Saxton, Chief Executive Officer of Baird Medical U.S. "In 2026, we are laying the commercial foundation for sustainable long-term growth in the U.S., building the team, infrastructure, and market awareness that this technology deserves. In parallel, Baird is investing in the further advancement of our MWA platform, with the goal of expanding our portfolio and broadening the addressable market over time. We look forward to sh...